On this page
⚠ Educational content only Not medical or genetic advice. Speak with a healthcare provider or genetic counsellor before acting on anything here.

RYR1

ryanodine receptor 1

The RYR1 gene encodes ryanodine receptor 1, a protein critical for calcium release in skeletal muscle cells, playing a key role in muscle contraction and relaxation. RYR1 provides the blueprint for the ryanodine receptor 1 protein, which functions as a calcium channel in skeletal muscles.

Chromosome 19q13.2 Autosomal dominant HGNC:10483 Tier C
RYR1 19q13.2 p arm q arm 19

RYR1 is located on the long (q) arm of chromosome 19, at band 19q13.2. Arm ratio per GRCh38 - banding schematic.

Explore chromosome 19 in the library →

Available at Jeen Health

Clinical tests that include this

Overview

The RYR1 gene directs the production of ryanodine receptor 1 protein, an essential component for normal skeletal muscle function. This protein forms a calcium release channel within muscle cells, which is fundamental for initiating muscle contraction. Understanding RYR1 is important for its role in both typical physiological processes and its association with several inherited muscle disorders.

Conditions linked to RYR1 variants include malignant hyperthermia susceptibility, central core disease, congenital fibre-type disproportion myopathy, and multi-minicore disease. These conditions frequently involve muscle weakness or abnormal reactions to certain anaesthetics, highlighting the gene's significance in neuromuscular health.

What the gene does

The RYR1 gene encodes the ryanodine receptor 1 (RYR1 channel) protein, a key player in excitation-contraction (E-C) coupling within skeletal muscles. This process converts electrical signals into muscle contraction. The RYR1 channel is embedded in the membrane of the sarcoplasmic reticulum, an intracellular compartment responsible for storing calcium ions.

When a muscle receives a signal to contract, the RYR1 channel opens, releasing stored calcium ions into the cell's cytoplasm. This influx of calcium ions triggers muscle fibres to contract, thereby facilitating movement. The proper functioning of the RYR1 channel is therefore crucial for the coordinated tensioning and relaxation of skeletal muscles. Variants in this gene can disrupt calcium regulation, leading to impaired muscle function.

Video: Genetics 101

Chromosome location

The RYR1 gene is situated on chromosome 19 at position 19q13.2. This genomic location specifies where the gene is found within the human genome. Its precise placement assists in genetic mapping and understanding the inheritance patterns of conditions associated with RYR1.

Protein structure

The ryanodine receptor 1 protein is a large protein composed of 5038 amino acids. It features several important structural domains. These include five MIR domains (MIR 1-5), three B30.2/SPRY domains (B30.2/SPRY 1-3), and an interaction region with FKBP1A. The protein also contains approximately six repeats within its central region and several disordered regions.

Domain map · 5,038 amino acids
MIR 1 (97-152)MIR 2 (159-204)MIR 3 (210-264)MIR 4 (270-327)MIR 5 (335-392)B30.2/SPRY 1 (581-797)B30.2/SPRY 2 (1013-1208)B30.2/SPRY 3 (1356-1570)B30.2/SPRY 1581-797B30.2/SPRY 21013-1208B30.2/SPRY 31356-15701~2,5195,038
Domain - independent functional unit
🧬 Explore 3D structure on AlphaFold
UniProt:P21817Length:5,038 aaStructure:AlphaFold

Key variants

Variants within the RYR1 gene can significantly impact the structure and function of the ryanodine receptor 1 protein. These genetic changes can alter how calcium is released within muscle cells, leading to a range of muscle-related conditions. The types of variants vary, from single amino acid substitutions to changes that result in truncated proteins, each potentially affecting the protein's ability to regulate calcium effectively.

The table below shows the top 10 pathogenic or likely-pathogenic variants currently classified in ClinVar for RYR1.
View all on ClinVar →

Sample of pathogenic variants

10 pathogenic / likely-pathogenic variants from ClinVar, ranked by review status (expert-panel-reviewed first). This is a sample; recurrent founder variants in a specific population may not appear here - see the full ClinVar listing via the link above.

Variant (HGVS) Protein change Classification Evidence Associated condition
c.10450dup
Duplication
p.Ile3484fs Pathogenic/Likely pathogenic ★★☆☆ Central core myopathy
c.2200C>T
single nucleotide variant
p.Gln734Ter Pathogenic/Likely pathogenic ★★☆☆ RYR1-related disorder
c.3883C>T
single nucleotide variant
p.Gln1295Ter Pathogenic/Likely pathogenic ★★☆☆ RYR1-related disorder
c.11653C>T
single nucleotide variant
p.Arg3885Ter Pathogenic ★☆☆☆ RYR1-related disorder
c.12511G>T
single nucleotide variant
p.Glu4171Ter Pathogenic ★☆☆☆ RYR1-related disorder
c.13048del
Deletion
p.Ala4350fs Pathogenic ★☆☆☆ RYR1-related disorder
c.13659+1del
Deletion
- Pathogenic ★☆☆☆ RYR1-related disorder
c.13671_13672delinsGT
Indel
p.Arg4558Trp Pathogenic ★☆☆☆ RYR1-related disorder
c.13867dup
Duplication
p.Asp4623fs Pathogenic ★☆☆☆ RYR1-related disorder
c.5804_5805del
Microsatellite
p.Val1935fs Pathogenic ★☆☆☆ Hypotonic infant

Evidence stars indicate ClinVar review status. Individual variant interpretation should always be performed by a qualified clinical laboratory - many variants remain classified as Variants of Uncertain Significance (VUS) pending more research.

Associated conditions

Variants in the RYR1 gene are linked to several inherited conditions that primarily affect skeletal muscles. These include Central core disease, characterised by muscle weakness, and Congenital fibre-type disproportion myopathy, which causes generalised muscle weakness. The gene is also a major genetic risk factor for Malignant hyperthermia susceptibility, a severe reaction to certain anaesthetics, and is associated with atypical forms of Multi-minicore disease.

Inheritance pattern

Conditions caused by pathogenic RYR1 variants typically follow autosomal dominant inheritance.

♀ Affected parent 1 altered copy ♂ Unaffected parent 2 typical copies Affected Unaffected Unaffected Affected Affected Carrier Unaffected Circles = females · Squares = males

Each child of an affected parent has a 50% chance of inheriting the pathogenic variant, regardless of sex.

Carrier frequency by population How common is heterozygous RYR1 carrier status across ancestry groups?

UK clinical status

In the UK, the RYR1 gene is reviewed by the NHS Genomic Medicine Service through its PanelApp framework. It is currently listed on several 'green' panels, indicating strong evidence for its association with specific conditions. These panels include Malignant hyperthermia, Congenital myopathy, Acute rhabdomyolysis, Arthrogryposis, Foetal anomalies, Foetal hydrops, Limb girdle muscular dystrophies, myofibrillar myopathies and distal myopathies, Rhabdomyolysis and metabolic muscle disorders, and Skeletal Muscle Channelopathies.

Frequently asked questions

What is the main function of the RYR1 gene?

The RYR1 gene provides instructions for making the ryanodine receptor 1 protein, which acts as a calcium release channel in skeletal muscle cells. This channel is crucial for initiating muscle contraction and relaxation.

What conditions are associated with RYR1 gene variants?

Variants in the RYR1 gene are associated with conditions such as Central core disease, Congenital fibre-type disproportion myopathy, Malignant hyperthermia susceptibility, and Multi-minicore disease, all of which affect muscle function.

How does RYR1 relate to malignant hyperthermia?

RYR1 gene variants are the most common genetic risk factor for malignant hyperthermia. This condition is a severe reaction to certain anaesthetic drugs, characterised by high fever and muscle rigidity, due to uncontrolled calcium release in muscle cells.

References

  1. Riazi S, Kraeva N, Hopkins PM. Malignant Hyperthermia in the Post-Genomics Era: New Perspectives on an Old Concept. Anesthesiology. 2018. PMID: 28902675
  2. Amburgey K, Bailey A, Hwang JH. Genotype-phenotype correlations in recessive RYR1-related myopathies. Orphanet journal of rare diseases. 2013. PMID: 23919265
  3. Clarke NF, Waddell LB, Cooper ST. Recessive mutations in RYR1 are a common cause of congenital fiber type disproportion. Human mutation. 2010. PMID: 20583297
  4. Lyfenko AD, Ducreux S, Wang Y. Two central core disease (CCD) deletions in the C-terminal region of RYR1 alter muscle excitation-contraction (EC) coupling by distinct mechanisms. Human mutation. 2007. PMID: 16958053
  5. Zorzato F, Jungbluth H, Zhou H. Functional effects of mutations identified in patients with multiminicore disease. IUBMB life. 2007. PMID: 17365175
  6. Zhou H, Jungbluth H, Sewry CA. Molecular mechanisms and phenotypic variation in RYR1-related congenital myopathies. Brain : a journal of neurology. 2007. PMID: 17483490
  7. Jungbluth H. Central core disease. Orphanet journal of rare diseases. 2007. PMID: 17504518
  8. Jungbluth H. Multi-minicore Disease. Orphanet journal of rare diseases. 2007. PMID: 17631035
  9. Rossi AE, Dirksen RT. Sarcoplasmic reticulum: the dynamic calcium governor of muscle. Muscle & nerve. 2006. PMID: 16477617
  10. Wu S, Ibarra MC, Malicdan MC. Central core disease is due to RYR1 mutations in more than 90% of patients. Brain : a journal of neurology. 2006. PMID: 16621918
  11. Robinson R, Carpenter D, Shaw MA. Mutations in RYR1 in malignant hyperthermia and central core disease. Human mutation. 2006. PMID: 16917943
  12. Avila G. Intracellular Ca2+ dynamics in malignant hyperthermia and central core disease: established concepts, new cellular mechanisms involved. Cell calcium. 2005. PMID: 15589992
  13. Treves S, Anderson AA, Ducreux S. Ryanodine receptor 1 mutations, dysregulation of calcium homeostasis and neuromuscular disorders. Neuromuscular disorders : NMD. 2005. PMID: 16084090
  14. Lyfenko AD, Goonasekera SA, Dirksen RT. Dynamic alterations in myoplasmic Ca2+ in malignant hyperthermia and central core disease. Biochemical and biophysical research communications. 2004. PMID: 15336973
  15. Adam MP, Bick S, Mirzaa GM. Nonsyndromic Malignant Hyperthermia Susceptibility. 1993. PMID: 20301325
Educational content. This page is not medical or genetic advice, is not individually reviewed by a clinician for each reader, and should not replace a consultation with a qualified healthcare professional or genetic counsellor. If you are considering genetic testing or acting on a test result, book a consultation.
Data sources Last updated 4 October 2026. Content compiled from HGNC · MedlinePlus Genetics · ClinGen · Genomics England PanelApp · NHS National Genomic Test Directory · ClinVar · UniProt · AlphaFold .